SCHAUMBURG, Ill., March 4, 2015 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB:WCUI) today announced that its wholly owned subsidiary, Psoria-Shield, Inc. (PSI), will be showcasing its flagship product, the Psoria-Light, at the 73rd Annual Meeting hosted by the American Academy of Dermatology (AAD) on March 20th through March 24th, at the Moscone Center in San Francisco, California.
The American Academy of Dermatology was founded in 1938. It is the largest, most influential, and most representative dermatology group in the United States. With a membership of more than 17,000, it represents virtually all practicing dermatologists in the United States, as well as a growing number of international dermatologists. Additionally, the AAD also publishes a monthly medical journal, the Journal of the American Academy of Dermatology.
Last year, the 72nd Annual Meeting hosted by AAD drew more than 15,000 attendees and featured world-renowned leaders presenting their studies in the field of dermatology.
Psoria-Shield, Inc.'s state-of-the-art device, the Psoria-Light, is the first in the world Deep UV LED Targeted Phototherapy system used to treat skin diseases such as Psoriasis, Eczema, and Vitiligo. Demand is high for Psoria-Shield's technology, and the 73rd Annual Meeting will be the optimal platform to showcase its unique capabilities. The Medical Alliance (TMA) will present Psoria-Shield, Inc.'s technology together with Quintessence Skin Science - in booth #1041.
Since the creation of its Joint Venture (J V) with The Medical Alliance in January, Psoria-Shield has made great progress in its efforts to manufacture, market and commercialize the Psoria-Light. Psoria-Shield is on track to begin revenue generation in the second quarter of 2015 and achieve second year revenues of $10M+ with a return of $2M EBITA.
Mr. John Yorke, Managing Director of TMA, stated, "We are enthusiastic with our progress to date in establishing new and efficient manufacturing procedures and methods which allow us to increase production efficiency and product reliability. Our corporate objective is to make Psoria-Light the Phototherapy solution of choice for physicians and service providers in treating psoriasis, eczema, and vitiligo. We are confident that our patented FDA approved product with its unique clinical advantages will make us a market leader in this field. We are excited and look forward to the AAD, which will commence our product commercialization."
Registration fees and important dates for the 73rd Annual Meeting can be found at:
https://www.aad.org/meetings/2015-annual-meeting/registration/registration-fees
More information about the American Academy of Dermatology and the 73rd Annual Meeting can be found at: https://www.aad.org/
About Wellness Center USA, Inc.
Wellness Center USA, Inc. (www.wellnesscenterusa.com) is a hybrid healthcare company that combines best in class technologies, software, devices, providers, protocols, goods, and services. It was created to address important healthcare and wellness needs via breakthrough solutions, all centered on the "well-being of the body and mind." Wellness Center USA, Inc. is the parent company of three businesses reporting consolidated: Stealth Mark, National Pain Centers, and Psoria-Shield.
About The Medical Alliance, Inc.
The Medical Alliance (TMA) (http://themedalliance.com) represents the 2013 merger of The ComedIT Group, Ocean Medical, and TFGI; combining over 75 years experience in delivering integrated consulting services to manufacturers, distributors, and candidates in the medical device, supply, and information technology arenas. TMA has offices in Amsterdam, the Netherlands, Utica, NY, Coconut Grove, FL and Jacksonville, FL. TMA works with an array of specialty consultants and has close affiliations with over 120 specialty medical search firms.
Safe Harbor Statement:
Certain statements and projections contained in this presentation that are not statements or financial results of historical fact constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements and projections include statements regarding any proposed exchange transactions, the anticipated closing date of such transactions and future results following a closing of the transactions. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like "believe," "expect," "anticipate," "pending," "estimate," and "intend" or future or conditional verbs such as "will," "would," "should," "could," or "may." While it is not possible to identify all factors, risks and uncertainties that might relate to, affect or arise from the proposed transactions and plans which might cause actual results to differ materially from expected results, such factors, risks and uncertainties include delays in completing the transactions, difficulties in integrating operations following the transactions, difficulties in manufacturing and delivering products, potential market rejection of products or services, increased competitive pressures, changes in general economic conditions, legislative and regulatory changes that adversely affect the business in which the parties are engaged, changes in the securities markets and other factors, risks and uncertainties disclosed from time to time in documents that the Company files with the SEC.